Darren R. Feldman, MD

Darren R. Feldman, MD

Genitourinary Oncologist

My Role at MSK

Areas of Expertise

My Specialties

  • Genitorinary Malignancies
  • Testicular Cancer (Germ Cell Tumors)
  • Kidney Cancer (Renal Cell Carcinoma)

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
English
Share

About Me

What I Do at MSK
  • Chair, Quality Assurance, Department of Medicine
  • Section Head, Germ Cell Cancer
Get To Know Me

I am a medical oncologist who cares for people with genitourinary cancer. I specialize in treating testicular cancer (germ cell tumors) and kidney cancer (renal cell carcinoma).

This provider is part of a team that was ranked #1 in the nation for Urology Cancer Care this year by U.S. News & World Report.

My research centers on developing new drugs or drug combinations for people with these cancers. I also lead national and international clinical trials for people with genitourinary cancer.

Read more

I became interested in cancer care at a very young age. My father is a medical oncologist. He took me on rounds with him when I was in high school and I appreciated the close relationships that oncologists develop with their patients. I was also drawn to the fascinating biology of how cancers form and progress. My career choice was solidified after being exposed to the leading-edge research and patient care at MSK while spending part of my residency and completing my fellowship here.

When I meet with people who have recently been diagnosed with cancer, my goal is to help them feel informed about their disease and treatment options. I want them to be confident that they are going to get the best care possible. I reassure them by discussing our vast experience with treating their illness and preventing and addressing treatment-related side effects. Studies have shown that people whose cancer is treated at an experienced cancer center like MSK achieve better outcomes than those treated at less specialized institutions. I am proud to be among the most experienced doctors caring for people with testicular cancer and kidney cancer. Equally as important, I treat my patients with compassion and respect, just as I would want my own family to be treated.

People with kidney cancer are now benefitting from advances made during the last 15 years, many led by researchers at MSK. We now have more treatment options than ever to help control the disease. Immunotherapy and targeted therapies combined with immunotherapy are producing unprecedented response rates and survival outcomes. My research in this area is examining the integration of PET imaging and radiolabeled targeted therapies for people with clear cell renal cancer, which has shown resistance to standard treatments. I am also working to better understand non-clear cell renal cancer, which is less common. 

I direct MSK’s testicular cancer research program, which addresses all aspects and stages of the disease. We are testing various therapies and the effectiveness of treatment combinations, including immunotherapy and targeted therapies. In fact, we are one of the only institutions in the world conducting studies to understand why some people develop germ cell tumors. We are also assessing the biologic basis for why some of these cancers are resistant to chemotherapy.

I also collaborate with the laboratory of David Solit. My colleagues and I are working to identify the molecular features of testicular cancer that could predict sensitivity or resistance to chemotherapy and overall patient outcomes. In addition, I concentrate on characterizing and preventing the long-term side effects of treatment for testicular cancer, such as heart disease, metabolic syndrome, and other cancers.

I have presented my research and lectured at meetings throughout the United States and in other countries.

Outside of work, I enjoy spending time with my wife and daughter, learning languages, reading mystery novels, and playing golf.

My Role at MSK

A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) oncologist is a cancer doctor with special training in the genitourinary (GU) system. This includes bladder, kidney, penis, prostate, and testicular cancers.

Areas of Expertise

My Specialties

  • Genitorinary Malignancies
  • Testicular Cancer (Germ Cell Tumors)
  • Kidney Cancer (Renal Cell Carcinoma)
Education & Honors

Education

  • MD, University of Maryland School of Medicine

Residencies

  • Internal Medicine - New York University School of Medicine
  • Chief Resident, Department of Medicine - Memorial Sloan Kettering Cancer Center

Awards and Honors

  • Castle Connolly: America’s Top Doctor (2024)
  • Top Doctors New York Metro Area, Castle Connolly (2023)
  • Castle Connolly: America's Top Doctors (2023)
  • Castle Connolly: New York Magazine Top Doctors (2014, 2016-2020)
  • John Mendelsohn Housestaff Teaching Award, Department of Medicine, Memorial Sloan Kettering Cancer Center (2005-2006)

Fellowships

  • Oncology/Hematology - Memorial Sloan Kettering Cancer Center

Board Certifications

  • Medical Oncology
  • Hematology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

MSK has a tentative agreement with Cigna to continue coverage in 2024.

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Feldman sees patients at one location.

Office Phone
Location
New York, NY

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Genitourinary Oncology Service doctors

Clinical Trials

Read more
Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Paclitaxel, ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors. J Clin Oncol. 2016 Jul 20;34(21):2478-83. 

Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol.  2016 Nov;34(32):3846-3853.  

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol. 2016 Nov;34(33):4000-4007.

Read more
Publications on PubMed

Visit PubMed for a full listing of Dr. Feldman’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Darren R. Feldman discloses the following relationships and financial interests:

  • BioNTech
    Professional Services and Activities
  • Telix Pharmaceuticals Limited
    Professional Services and Activities
  • UptoDate
    Intellectual Property Rights

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures